<DOC>
	<DOCNO>NCT01475253</DOCNO>
	<brief_summary>The purpose study determine LiRIS® , investigational drug-delivery system , safe , tolerable effective woman Interstitial Cystitis . LiRIS® inserted bladder via cystoscopy , remain bladder 14 day , remove via cystoscopy .</brief_summary>
	<brief_title>Double-Blind Placebo Controlled Study Safety , Tolerability , Efficacy LiRIS® Women With Interstitial Cystitis</brief_title>
	<detailed_description>The study conduct 2 part - randomize , blind part patient randomly assign one 3 possible arm ( LiRIS® - contains lidocaine ) , LiRIS Placebo ( LiRIS inactive substance ) Sham ( Insertion procedure neither LiRIS LiRIS Placebo ) , follow open extension part patient assign receive LiRIS® ( lidocaine ) . In part 1 study , treatment manage double-blind manner LiRIS® LiRIS Placebo arm ; single-blind manner Sham arm ( e.g. , study doctor know treatment assignment patient assign Sham ) . All patient complete part 1 study option enter extension .</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Women age 18 Diagnosed Interstitial Cystitis define protocol Able willing complete questionnaire diary Able comply visit schedule include Day 14 Removal visit Completion blind study prior enrol unblinded part study Pregnant lactate woman Bladder urethra anatomical feature would prevent safe indwell insertion investigational product History presence condition would make difficult evaluate symptom Did complete blind study ( unblinded part study )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>